Product Sales year-on-year analysis: Q2 2025 (Details) - USD ($)
$ in Millions |
3 Months Ended |
6 Months Ended |
Jun. 30, 2025 |
Jun. 30, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
| Product sales |
|
|
|
|
| Product Sales |
$ 13,795
|
$ 12,452
|
$ 26,670
|
$ 24,629
|
| Actual %, year-on-year |
11.00%
|
|
8.00%
|
|
| CER %, year-on-year |
10.00%
|
|
10.00%
|
|
| US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 5,852
|
|
$ 11,085
|
|
| Actual %, year-on-year |
12.00%
|
|
10.00%
|
|
| Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 3,705
|
|
$ 7,598
|
|
| Actual %, year-on-year |
11.00%
|
|
8.00%
|
|
| CER %, year-on-year |
13.00%
|
|
12.00%
|
|
| Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 2,946
|
|
$ 5,568
|
|
| Actual %, year-on-year |
12.00%
|
|
8.00%
|
|
| CER %, year-on-year |
8.00%
|
|
8.00%
|
|
| Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1,292
|
|
$ 2,419
|
|
| Actual %, year-on-year |
4.00%
|
|
2.00%
|
|
| CER %, year-on-year |
1.00%
|
|
2.00%
|
|
| Total Oncology |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 5,854
|
|
$ 11,085
|
|
| Actual %, year-on-year |
18.00%
|
|
14.00%
|
|
| CER %, year-on-year |
17.00%
|
|
15.00%
|
|
| Total Oncology | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 2,770
|
|
$ 5,167
|
|
| Actual %, year-on-year |
20.00%
|
|
18.00%
|
|
| Total Oncology | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1,310
|
|
$ 2,628
|
|
| Actual %, year-on-year |
19.00%
|
|
14.00%
|
|
| CER %, year-on-year |
22.00%
|
|
19.00%
|
|
| Total Oncology | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1,183
|
|
$ 2,215
|
|
| Actual %, year-on-year |
17.00%
|
|
13.00%
|
|
| CER %, year-on-year |
12.00%
|
|
12.00%
|
|
| Total Oncology | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 591
|
|
$ 1,075
|
|
| Actual %, year-on-year |
5.00%
|
|
(1.00%)
|
|
| CER %, year-on-year |
2.00%
|
|
|
|
| Tagrisso |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1,810
|
|
$ 3,488
|
|
| Actual %, year-on-year |
13.00%
|
|
9.00%
|
|
| CER %, year-on-year |
12.00%
|
|
10.00%
|
|
| Tagrisso | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 761
|
|
$ 1,439
|
|
| Actual %, year-on-year |
16.00%
|
|
12.00%
|
|
| Tagrisso | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 489
|
|
$ 1,008
|
|
| Actual %, year-on-year |
13.00%
|
|
10.00%
|
|
| CER %, year-on-year |
15.00%
|
|
13.00%
|
|
| Tagrisso | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 351
|
|
$ 658
|
|
| Actual %, year-on-year |
8.00%
|
|
5.00%
|
|
| CER %, year-on-year |
4.00%
|
|
5.00%
|
|
| Tagrisso | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 209
|
|
$ 383
|
|
| Actual %, year-on-year |
9.00%
|
|
3.00%
|
|
| CER %, year-on-year |
5.00%
|
|
3.00%
|
|
| Imfinzi |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1,455
|
|
$ 2,716
|
|
| Actual %, year-on-year |
27.00%
|
|
20.00%
|
|
| CER %, year-on-year |
26.00%
|
|
21.00%
|
|
| Imfinzi | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 844
|
|
$ 1,572
|
|
| Actual %, year-on-year |
36.00%
|
|
31.00%
|
|
| Imfinzi | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 152
|
|
$ 294
|
|
| Actual %, year-on-year |
31.00%
|
|
20.00%
|
|
| CER %, year-on-year |
35.00%
|
|
28.00%
|
|
| Imfinzi | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 285
|
|
$ 537
|
|
| Actual %, year-on-year |
26.00%
|
|
17.00%
|
|
| CER %, year-on-year |
21.00%
|
|
17.00%
|
|
| Imfinzi | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 174
|
|
$ 313
|
|
| Actual %, year-on-year |
(5.00%)
|
|
(11.00%)
|
|
| CER %, year-on-year |
(8.00%)
|
|
(11.00%)
|
|
| Calquence |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 872
|
|
$ 1,634
|
|
| Actual %, year-on-year |
10.00%
|
|
8.00%
|
|
| CER %, year-on-year |
10.00%
|
|
9.00%
|
|
| Calquence | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 583
|
|
$ 1,090
|
|
| Actual %, year-on-year |
5.00%
|
|
4.00%
|
|
| Calquence | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 49
|
|
$ 103
|
|
| Actual %, year-on-year |
36.00%
|
|
36.00%
|
|
| CER %, year-on-year |
43.00%
|
|
49.00%
|
|
| Calquence | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 198
|
|
$ 368
|
|
| Actual %, year-on-year |
19.00%
|
|
15.00%
|
|
| CER %, year-on-year |
14.00%
|
|
15.00%
|
|
| Calquence | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 42
|
|
$ 73
|
|
| Actual %, year-on-year |
27.00%
|
|
12.00%
|
|
| CER %, year-on-year |
28.00%
|
|
15.00%
|
|
| Lynparza |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 838
|
|
$ 1,564
|
|
| Actual %, year-on-year |
13.00%
|
|
8.00%
|
|
| CER %, year-on-year |
11.00%
|
|
9.00%
|
|
| Lynparza | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 378
|
|
$ 689
|
|
| Actual %, year-on-year |
18.00%
|
|
14.00%
|
|
| Lynparza | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 162
|
|
$ 323
|
|
| Actual %, year-on-year |
6.00%
|
|
1.00%
|
|
| CER %, year-on-year |
7.00%
|
|
4.00%
|
|
| Lynparza | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 229
|
|
$ 425
|
|
| Actual %, year-on-year |
11.00%
|
|
7.00%
|
|
| CER %, year-on-year |
7.00%
|
|
6.00%
|
|
| Lynparza | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 69
|
|
$ 127
|
|
| Actual %, year-on-year |
5.00%
|
|
1.00%
|
|
| CER %, year-on-year |
2.00%
|
|
2.00%
|
|
| Enhertu |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 230
|
|
$ 428
|
|
| Actual %, year-on-year |
81.00%
|
|
72.00%
|
|
| CER %, year-on-year |
82.00%
|
|
76.00%
|
|
| Enhertu | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 156
|
|
$ 292
|
|
| Actual %, year-on-year |
|
|
82.00%
|
|
| CER %, year-on-year |
|
|
88.00%
|
|
| Enhertu | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 51
|
|
$ 94
|
|
| Actual %, year-on-year |
63.00%
|
|
65.00%
|
|
| CER %, year-on-year |
56.00%
|
|
63.00%
|
|
| Enhertu | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 23
|
|
$ 42
|
|
| Actual %, year-on-year |
24.00%
|
|
35.00%
|
|
| CER %, year-on-year |
28.00%
|
|
41.00%
|
|
| Zoladex |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 284
|
|
$ 567
|
|
| Actual %, year-on-year |
4.00%
|
|
3.00%
|
|
| CER %, year-on-year |
5.00%
|
|
6.00%
|
|
| Zoladex | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 4
|
|
$ 9
|
|
| Actual %, year-on-year |
(8.00%)
|
|
16.00%
|
|
| Zoladex | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 219
|
|
$ 442
|
|
| Actual %, year-on-year |
9.00%
|
|
7.00%
|
|
| CER %, year-on-year |
11.00%
|
|
10.00%
|
|
| Zoladex | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 38
|
|
$ 72
|
|
| Actual %, year-on-year |
(9.00%)
|
|
(7.00%)
|
|
| CER %, year-on-year |
(13.00%)
|
|
(8.00%)
|
|
| Zoladex | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 23
|
|
$ 44
|
|
| Actual %, year-on-year |
(9.00%)
|
|
(10.00%)
|
|
| CER %, year-on-year |
(11.00%)
|
|
(9.00%)
|
|
| Truqap |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 170
|
|
$ 302
|
|
| Actual %, year-on-year |
84.00%
|
|
|
|
| CER %, year-on-year |
84.00%
|
|
|
|
| Truqap | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 142
|
|
$ 253
|
|
| Actual %, year-on-year |
57.00%
|
|
80.00%
|
|
| Truqap | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 6
|
|
$ 8
|
|
| Truqap | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
14
|
|
28
|
|
| Truqap | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
8
|
|
13
|
|
| Imjudo |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 89
|
|
$ 170
|
|
| Actual %, year-on-year |
20.00%
|
|
25.00%
|
|
| CER %, year-on-year |
18.00%
|
|
25.00%
|
|
| Imjudo | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 57
|
|
$ 111
|
|
| Actual %, year-on-year |
17.00%
|
|
26.00%
|
|
| Imjudo | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 7
|
|
$ 12
|
|
| Actual %, year-on-year |
93.00%
|
|
58.00%
|
|
| CER %, year-on-year |
84.00%
|
|
68.00%
|
|
| Imjudo | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 12
|
|
$ 23
|
|
| Actual %, year-on-year |
39.00%
|
|
43.00%
|
|
| CER %, year-on-year |
35.00%
|
|
43.00%
|
|
| Imjudo | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 13
|
|
$ 24
|
|
| Actual %, year-on-year |
|
|
(1.00%)
|
|
| CER %, year-on-year |
(4.00%)
|
|
(2.00%)
|
|
| Oncology, Others |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 106
|
|
$ 216
|
|
| Actual %, year-on-year |
(12.00%)
|
|
(10.00%)
|
|
| CER %, year-on-year |
(13.00%)
|
|
(8.00%)
|
|
| Oncology, Others | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1
|
|
$ 4
|
|
| Actual %, year-on-year |
(76.00%)
|
|
(63.00%)
|
|
| Oncology, Others | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 70
|
|
$ 146
|
|
| Actual %, year-on-year |
(11.00%)
|
|
(7.00%)
|
|
| CER %, year-on-year |
(10.00%)
|
|
(5.00%)
|
|
| Oncology, Others | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 5
|
|
$ 10
|
|
| Actual %, year-on-year |
(27.00%)
|
|
(16.00%)
|
|
| CER %, year-on-year |
(30.00%)
|
|
(16.00%)
|
|
| Oncology, Others | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 30
|
|
$ 56
|
|
| Actual %, year-on-year |
|
|
(6.00%)
|
|
| CER %, year-on-year |
(5.00%)
|
|
(7.00%)
|
|
| BioPharmaceuticals: total CVRM |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 3,261
|
|
$ 6,505
|
|
| Actual %, year-on-year |
3.00%
|
|
6.00%
|
|
| CER %, year-on-year |
3.00%
|
|
7.00%
|
|
| BioPharmaceuticals: total CVRM | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 665
|
|
$ 1,351
|
|
| Actual %, year-on-year |
(10.00%)
|
|
(9.00%)
|
|
| BioPharmaceuticals: total CVRM | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1,512
|
|
$ 3,064
|
|
| Actual %, year-on-year |
9.00%
|
|
11.00%
|
|
| CER %, year-on-year |
11.00%
|
|
15.00%
|
|
| BioPharmaceuticals: total CVRM | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 889
|
|
$ 1,696
|
|
| Actual %, year-on-year |
5.00%
|
|
9.00%
|
|
| CER %, year-on-year |
1.00%
|
|
9.00%
|
|
| BioPharmaceuticals: total CVRM | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 195
|
|
$ 394
|
|
| Actual %, year-on-year |
2.00%
|
|
6.00%
|
|
| CER %, year-on-year |
(2.00%)
|
|
6.00%
|
|
| Farxiga |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 2,150
|
|
$ 4,206
|
|
| Actual %, year-on-year |
11.00%
|
|
11.00%
|
|
| CER %, year-on-year |
10.00%
|
|
13.00%
|
|
| Farxiga | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 420
|
|
$ 803
|
|
| Actual %, year-on-year |
6.00%
|
|
(7.00%)
|
|
| Farxiga | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 859
|
|
$ 1,730
|
|
| Actual %, year-on-year |
13.00%
|
|
17.00%
|
|
| CER %, year-on-year |
15.00%
|
|
23.00%
|
|
| Farxiga | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 765
|
|
$ 1,448
|
|
| Actual %, year-on-year |
13.00%
|
|
17.00%
|
|
| CER %, year-on-year |
8.00%
|
|
17.00%
|
|
| Farxiga | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 106
|
|
$ 225
|
|
| Actual %, year-on-year |
3.00%
|
|
7.00%
|
|
| CER %, year-on-year |
(1.00%)
|
|
7.00%
|
|
| Crestor |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 319
|
|
$ 635
|
|
| Actual %, year-on-year |
9.00%
|
|
8.00%
|
|
| CER %, year-on-year |
9.00%
|
|
10.00%
|
|
| Crestor | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 12
|
|
$ 24
|
|
| Actual %, year-on-year |
3.00%
|
|
11.00%
|
|
| Crestor | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 275
|
|
$ 547
|
|
| Actual %, year-on-year |
17.00%
|
|
15.00%
|
|
| CER %, year-on-year |
18.00%
|
|
17.00%
|
|
| Crestor | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 32
|
|
$ 64
|
|
| Actual %, year-on-year |
(10.00%)
|
|
(9.00%)
|
|
| CER %, year-on-year |
(13.00%)
|
|
(8.00%)
|
|
| Brilinta |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 215
|
|
$ 520
|
|
| Actual %, year-on-year |
(37.00%)
|
|
(22.00%)
|
|
| CER %, year-on-year |
(38.00%)
|
|
(21.00%)
|
|
| Brilinta | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 99
|
|
$ 271
|
|
| Actual %, year-on-year |
(48.00%)
|
|
(23.00%)
|
|
| Brilinta | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 63
|
|
$ 137
|
|
| Actual %, year-on-year |
(20.00%)
|
|
(18.00%)
|
|
| CER %, year-on-year |
(20.00%)
|
|
(16.00%)
|
|
| Brilinta | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 51
|
|
$ 107
|
|
| Actual %, year-on-year |
(26.00%)
|
|
(21.00%)
|
|
| CER %, year-on-year |
(29.00%)
|
|
(21.00%)
|
|
| Brilinta | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 2
|
|
$ 5
|
|
| Actual %, year-on-year |
(46.00%)
|
|
(39.00%)
|
|
| CER %, year-on-year |
(39.00%)
|
|
(34.00%)
|
|
| Seloken |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 148
|
|
$ 308
|
|
| Actual %, year-on-year |
(2.00%)
|
|
(2.00%)
|
|
| CER %, year-on-year |
1.00%
|
|
2.00%
|
|
| Seloken | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 143
|
|
$ 298
|
|
| Actual %, year-on-year |
(2.00%)
|
|
(3.00%)
|
|
| CER %, year-on-year |
|
|
1.00%
|
|
| Seloken | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 4
|
|
$ 8
|
|
| Actual %, year-on-year |
4.00%
|
|
34.00%
|
|
| CER %, year-on-year |
11.00%
|
|
38.00%
|
|
| Seloken | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1
|
|
$ 2
|
|
| Actual %, year-on-year |
(5.00%)
|
|
(9.00%)
|
|
| CER %, year-on-year |
(3.00%)
|
|
(5.00%)
|
|
| Lokelma |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 175
|
|
$ 328
|
|
| Actual %, year-on-year |
29.00%
|
|
31.00%
|
|
| CER %, year-on-year |
27.00%
|
|
32.00%
|
|
| Lokelma | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 75
|
|
$ 144
|
|
| Actual %, year-on-year |
18.00%
|
|
25.00%
|
|
| Lokelma | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 33
|
|
$ 63
|
|
| Actual %, year-on-year |
52.00%
|
|
50.00%
|
|
| CER %, year-on-year |
54.00%
|
|
54.00%
|
|
| Lokelma | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 30
|
|
$ 56
|
|
| Actual %, year-on-year |
33.00%
|
|
36.00%
|
|
| CER %, year-on-year |
29.00%
|
|
36.00%
|
|
| Lokelma | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 37
|
|
$ 65
|
|
| Actual %, year-on-year |
30.00%
|
|
27.00%
|
|
| CER %, year-on-year |
24.00%
|
|
26.00%
|
|
| roxadustat |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 72
|
|
$ 150
|
|
| Actual %, year-on-year |
(18.00%)
|
|
(8.00%)
|
|
| CER %, year-on-year |
(18.00%)
|
|
(7.00%)
|
|
| roxadustat | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 72
|
|
$ 150
|
|
| Actual %, year-on-year |
(18.00%)
|
|
(8.00%)
|
|
| CER %, year-on-year |
(18.00%)
|
|
(7.00%)
|
|
| Wainua |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 44
|
|
$ 84
|
|
| Wainua | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
43
|
|
82
|
|
| Wainua | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
|
|
1
|
|
| Wainua | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
1
|
|
1
|
|
| CVRM, Others |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 138
|
|
$ 274
|
|
| Actual %, year-on-year |
(27.00%)
|
|
(27.00%)
|
|
| CER %, year-on-year |
(28.00%)
|
|
(26.00%)
|
|
| CVRM, Others | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 16
|
|
$ 27
|
|
| Actual %, year-on-year |
(73.00%)
|
|
(74.00%)
|
|
| CVRM, Others | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 67
|
|
$ 138
|
|
| Actual %, year-on-year |
24.00%
|
|
14.00%
|
|
| CER %, year-on-year |
24.00%
|
|
16.00%
|
|
| CVRM, Others | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 38
|
|
$ 76
|
|
| Actual %, year-on-year |
(35.00%)
|
|
(37.00%)
|
|
| CER %, year-on-year |
(37.00%)
|
|
(37.00%)
|
|
| CVRM, Others | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 17
|
|
$ 33
|
|
| Actual %, year-on-year |
(8.00%)
|
|
7.00%
|
|
| CER %, year-on-year |
(12.00%)
|
|
7.00%
|
|
| BioPharmaceuticals: total Respiratory & Immunology |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1,988
|
|
$ 3,935
|
|
| Actual %, year-on-year |
11.00%
|
|
9.00%
|
|
| CER %, year-on-year |
10.00%
|
|
10.00%
|
|
| BioPharmaceuticals: total Respiratory & Immunology | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 977
|
|
$ 1,842
|
|
| Actual %, year-on-year |
18.00%
|
|
18.00%
|
|
| BioPharmaceuticals: total Respiratory & Immunology | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 381
|
|
$ 910
|
|
| Actual %, year-on-year |
(14.00%)
|
|
(12.00%)
|
|
| CER %, year-on-year |
(13.00%)
|
|
(9.00%)
|
|
| BioPharmaceuticals: total Respiratory & Immunology | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 422
|
|
$ 800
|
|
| Actual %, year-on-year |
21.00%
|
|
18.00%
|
|
| CER %, year-on-year |
16.00%
|
|
17.00%
|
|
| BioPharmaceuticals: total Respiratory & Immunology | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 208
|
|
$ 383
|
|
| Actual %, year-on-year |
20.00%
|
|
19.00%
|
|
| CER %, year-on-year |
19.00%
|
|
21.00%
|
|
| Symbicort |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 715
|
|
$ 1,438
|
|
| Actual %, year-on-year |
(1.00%)
|
|
(4.00%)
|
|
| CER %, year-on-year |
(1.00%)
|
|
(2.00%)
|
|
| Symbicort | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 319
|
|
$ 598
|
|
| Actual %, year-on-year |
7.00%
|
|
|
|
| Symbicort | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 168
|
|
$ 400
|
|
| Actual %, year-on-year |
(15.00%)
|
|
(11.00%)
|
|
| CER %, year-on-year |
(14.00%)
|
|
(8.00%)
|
|
| Symbicort | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 137
|
|
$ 272
|
|
| Actual %, year-on-year |
(5.00%)
|
|
(5.00%)
|
|
| CER %, year-on-year |
(8.00%)
|
|
(5.00%)
|
|
| Symbicort | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 91
|
|
$ 168
|
|
| Actual %, year-on-year |
11.00%
|
|
7.00%
|
|
| CER %, year-on-year |
11.00%
|
|
10.00%
|
|
| Fasenra |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 502
|
|
$ 920
|
|
| Actual %, year-on-year |
19.00%
|
|
18.00%
|
|
| CER %, year-on-year |
18.00%
|
|
18.00%
|
|
| Fasenra | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 307
|
|
$ 556
|
|
| Actual %, year-on-year |
14.00%
|
|
16.00%
|
|
| Fasenra | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 26
|
|
$ 52
|
|
| Actual %, year-on-year |
33.00%
|
|
26.00%
|
|
| CER %, year-on-year |
36.00%
|
|
32.00%
|
|
| Fasenra | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 125
|
|
$ 229
|
|
| Actual %, year-on-year |
27.00%
|
|
19.00%
|
|
| CER %, year-on-year |
22.00%
|
|
19.00%
|
|
| Fasenra | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 44
|
|
$ 83
|
|
| Actual %, year-on-year |
20.00%
|
|
19.00%
|
|
| CER %, year-on-year |
18.00%
|
|
20.00%
|
|
| Breztri |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 283
|
|
$ 583
|
|
| Actual %, year-on-year |
21.00%
|
|
28.00%
|
|
| CER %, year-on-year |
20.00%
|
|
29.00%
|
|
| Breztri | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 147
|
|
$ 295
|
|
| Actual %, year-on-year |
22.00%
|
|
31.00%
|
|
| Breztri | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 65
|
|
$ 156
|
|
| Actual %, year-on-year |
7.00%
|
|
19.00%
|
|
| CER %, year-on-year |
8.00%
|
|
21.00%
|
|
| Breztri | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 46
|
|
$ 87
|
|
| Actual %, year-on-year |
32.00%
|
|
34.00%
|
|
| CER %, year-on-year |
27.00%
|
|
34.00%
|
|
| Breztri | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 25
|
|
$ 45
|
|
| Actual %, year-on-year |
30.00%
|
|
34.00%
|
|
| CER %, year-on-year |
28.00%
|
|
36.00%
|
|
| Tezspire |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 112
|
|
$ 198
|
|
| Actual %, year-on-year |
97.00%
|
|
99.00%
|
|
| CER %, year-on-year |
91.00%
|
|
|
|
| Tezspire | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 9
|
|
$ 16
|
|
| Tezspire | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
72
|
|
128
|
|
| Tezspire | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 31
|
|
$ 54
|
|
| Actual %, year-on-year |
60.00%
|
|
61.00%
|
|
| CER %, year-on-year |
55.00%
|
|
63.00%
|
|
| Pulmicort |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 106
|
|
$ 264
|
|
| Actual %, year-on-year |
(32.00%)
|
|
(30.00%)
|
|
| CER %, year-on-year |
(32.00%)
|
|
(28.00%)
|
|
| Pulmicort | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1
|
|
$ 4
|
|
| Actual %, year-on-year |
(58.00%)
|
|
(57.00%)
|
|
| Pulmicort | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 81
|
|
$ 208
|
|
| Actual %, year-on-year |
(35.00%)
|
|
(34.00%)
|
|
| CER %, year-on-year |
(36.00%)
|
|
(32.00%)
|
|
| Pulmicort | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 15
|
|
$ 34
|
|
| Actual %, year-on-year |
(14.00%)
|
|
(8.00%)
|
|
| CER %, year-on-year |
(18.00%)
|
|
(7.00%)
|
|
| Pulmicort | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 9
|
|
$ 18
|
|
| Actual %, year-on-year |
2.00%
|
|
8.00%
|
|
| CER %, year-on-year |
2.00%
|
|
11.00%
|
|
| Saphnelo |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 167
|
|
$ 304
|
|
| Actual %, year-on-year |
49.00%
|
|
49.00%
|
|
| CER %, year-on-year |
48.00%
|
|
49.00%
|
|
| Saphnelo | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 145
|
|
$ 265
|
|
| Actual %, year-on-year |
44.00%
|
|
44.00%
|
|
| Saphnelo | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 4
|
|
$ 7
|
|
| Saphnelo | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
12
|
|
21
|
|
| Saphnelo | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 6
|
|
$ 11
|
|
| Actual %, year-on-year |
41.00%
|
|
45.00%
|
|
| CER %, year-on-year |
31.00%
|
|
45.00%
|
|
| Airsupra |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 42
|
|
$ 70
|
|
| Airsupra | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
42
|
|
69
|
|
| Airsupra | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
|
|
1
|
|
| Respiratory, Others |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 61
|
|
$ 158
|
|
| Actual %, year-on-year |
(23.00%)
|
|
(8.00%)
|
|
| CER %, year-on-year |
(24.00%)
|
|
(8.00%)
|
|
| Respiratory, Others | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 16
|
|
$ 55
|
|
| Actual %, year-on-year |
(35.00%)
|
|
4.00%
|
|
| Respiratory, Others | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 28
|
|
$ 70
|
|
| Actual %, year-on-year |
(25.00%)
|
|
(18.00%)
|
|
| CER %, year-on-year |
(25.00%)
|
|
(17.00%)
|
|
| Respiratory, Others | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 15
|
|
$ 29
|
|
| Actual %, year-on-year |
2.00%
|
|
(2.00%)
|
|
| CER %, year-on-year |
(3.00%)
|
|
(3.00%)
|
|
| Respiratory, Others | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 2
|
|
$ 4
|
|
| Actual %, year-on-year |
(8.00%)
|
|
(4.00%)
|
|
| CER %, year-on-year |
(7.00%)
|
|
|
|
| BioPharmaceuticals: Total V&I |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 157
|
|
$ 301
|
|
| Actual %, year-on-year |
40.00%
|
|
(7.00%)
|
|
| CER %, year-on-year |
42.00%
|
|
(5.00%)
|
|
| BioPharmaceuticals: Total V&I | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 73
|
|
$ 101
|
|
| Actual %, year-on-year |
|
|
82.00%
|
|
| BioPharmaceuticals: Total V&I | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 38
|
|
$ 121
|
|
| Actual %, year-on-year |
(6.00%)
|
|
(7.00%)
|
|
| CER %, year-on-year |
(1.00%)
|
|
(3.00%)
|
|
| BioPharmaceuticals: Total V&I | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 24
|
|
$ 50
|
|
| Actual %, year-on-year |
|
|
(39.00%)
|
|
| CER %, year-on-year |
|
|
37.00%
|
|
| BioPharmaceuticals: Total V&I | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 22
|
|
$ 29
|
|
| Actual %, year-on-year |
(39.00%)
|
|
(49.00%)
|
|
| CER %, year-on-year |
(40.00%)
|
|
(50.00%)
|
|
| Beyfortus |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 98
|
|
$ 128
|
|
| Beyfortus | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
73
|
|
$ 102
|
|
| Actual %, year-on-year |
|
|
91.00%
|
|
| Beyfortus | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
24
|
|
$ 24
|
|
| Beyfortus | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1
|
|
2
|
|
| Actual %, year-on-year |
34.00%
|
|
|
|
| CER %, year-on-year |
27.00%
|
|
|
|
| Synagis |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 49
|
|
$ 162
|
|
| Actual %, year-on-year |
(39.00%)
|
|
(36.00%)
|
|
| CER %, year-on-year |
(37.00%)
|
|
(33.00%)
|
|
| Synagis | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product sales net of reversals |
|
|
$ (1)
|
|
| Actual %, year-on-year |
|
|
(22.00%)
|
|
| Synagis | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 38
|
|
$ 121
|
|
| Actual %, year-on-year |
(7.00%)
|
|
(8.00%)
|
|
| CER %, year-on-year |
(1.00%)
|
|
(3.00%)
|
|
| Synagis | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
|
|
$ 25
|
|
| Actual %, year-on-year |
|
|
(62.00%)
|
|
| CER %, year-on-year |
|
|
(60.00%)
|
|
| Synagis | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 11
|
|
$ 17
|
|
| Actual %, year-on-year |
(68.00%)
|
|
(70.00%)
|
|
| CER %, year-on-year |
(69.00%)
|
|
(71.00%)
|
|
| FluMist |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 10
|
|
$ 10
|
|
| Actual %, year-on-year |
|
|
20.00%
|
|
| CER %, year-on-year |
|
|
16.00%
|
|
| FluMist | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
10
|
|
$ 10
|
|
| Total rare diseases |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 2,294
|
|
$ 4,336
|
|
| Actual %, year-on-year |
7.00%
|
|
2.00%
|
|
| CER %, year-on-year |
7.00%
|
|
3.00%
|
|
| Total rare diseases | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1,346
|
|
$ 2,584
|
|
| Actual %, year-on-year |
3.00%
|
|
3.00%
|
|
| Total rare diseases | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 278
|
|
$ 483
|
|
| Actual %, year-on-year |
37.00%
|
|
6.00%
|
|
| CER %, year-on-year |
48.00%
|
|
16.00%
|
|
| Total rare diseases | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 412
|
|
$ 772
|
|
| Actual %, year-on-year |
5.00%
|
|
(3.00%)
|
|
| CER %, year-on-year |
1.00%
|
|
(3.00%)
|
|
| Total rare diseases | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 258
|
|
$ 497
|
|
| Actual %, year-on-year |
7.00%
|
|
4.00%
|
|
| CER %, year-on-year |
2.00%
|
|
4.00%
|
|
| Ultomiris |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1,177
|
|
$ 2,228
|
|
| Actual %, year-on-year |
25.00%
|
|
23.00%
|
|
| CER %, year-on-year |
23.00%
|
|
24.00%
|
|
| Ultomiris | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 667
|
|
$ 1,272
|
|
| Actual %, year-on-year |
21.00%
|
|
23.00%
|
|
| Ultomiris | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 61
|
|
$ 113
|
|
| Actual %, year-on-year |
76.00%
|
|
71.00%
|
|
| CER %, year-on-year |
86.00%
|
|
82.00%
|
|
| Ultomiris | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 270
|
|
$ 498
|
|
| Actual %, year-on-year |
29.00%
|
|
21.00%
|
|
| CER %, year-on-year |
24.00%
|
|
21.00%
|
|
| Ultomiris | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 179
|
|
$ 345
|
|
| Actual %, year-on-year |
18.00%
|
|
17.00%
|
|
| CER %, year-on-year |
12.00%
|
|
17.00%
|
|
| Soliris |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 530
|
|
$ 974
|
|
| Actual %, year-on-year |
(24.00%)
|
|
(32.00%)
|
|
| CER %, year-on-year |
(22.00%)
|
|
(30.00%)
|
|
| Soliris | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 280
|
|
$ 568
|
|
| Actual %, year-on-year |
(30.00%)
|
|
(30.00%)
|
|
| Soliris | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 159
|
|
$ 224
|
|
| Actual %, year-on-year |
23.00%
|
|
(12.00%)
|
|
| CER %, year-on-year |
38.00%
|
|
(1.00%)
|
|
| Soliris | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 56
|
|
$ 112
|
|
| Actual %, year-on-year |
(52.00%)
|
|
(57.00%)
|
|
| CER %, year-on-year |
(54.00%)
|
|
(57.00%)
|
|
| Soliris | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 35
|
|
$ 70
|
|
| Actual %, year-on-year |
(37.00%)
|
|
(40.00%)
|
|
| CER %, year-on-year |
(38.00%)
|
|
(38.00%)
|
|
| Strensiq |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 395
|
|
$ 746
|
|
| Actual %, year-on-year |
16.00%
|
|
14.00%
|
|
| CER %, year-on-year |
15.00%
|
|
15.00%
|
|
| Strensiq | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 319
|
|
$ 584
|
|
| Actual %, year-on-year |
12.00%
|
|
10.00%
|
|
| Strensiq | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 16
|
|
$ 50
|
|
| Actual %, year-on-year |
65.00%
|
|
61.00%
|
|
| CER %, year-on-year |
58.00%
|
|
67.00%
|
|
| Strensiq | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 31
|
|
$ 57
|
|
| Actual %, year-on-year |
30.00%
|
|
19.00%
|
|
| CER %, year-on-year |
26.00%
|
|
20.00%
|
|
| Strensiq | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 29
|
|
$ 55
|
|
| Actual %, year-on-year |
27.00%
|
|
24.00%
|
|
| CER %, year-on-year |
21.00%
|
|
23.00%
|
|
| Koselugo |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 137
|
|
$ 275
|
|
| Actual %, year-on-year |
20.00%
|
|
11.00%
|
|
| CER %, year-on-year |
18.00%
|
|
13.00%
|
|
| Koselugo | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 52
|
|
$ 106
|
|
| Actual %, year-on-year |
(5.00%)
|
|
5.00%
|
|
| Koselugo | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 36
|
|
$ 76
|
|
| Actual %, year-on-year |
51.00%
|
|
(9.00%)
|
|
| CER %, year-on-year |
50.00%
|
|
(5.00%)
|
|
| Koselugo | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 37
|
|
$ 71
|
|
| Actual %, year-on-year |
42.00%
|
|
58.00%
|
|
| CER %, year-on-year |
37.00%
|
|
58.00%
|
|
| Koselugo | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 12
|
|
$ 22
|
|
| Actual %, year-on-year |
28.00%
|
|
25.00%
|
|
| CER %, year-on-year |
22.00%
|
|
25.00%
|
|
| Other Rare Disease |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 55
|
|
$ 113
|
|
| Actual %, year-on-year |
16.00%
|
|
12.00%
|
|
| CER %, year-on-year |
14.00%
|
|
14.00%
|
|
| Other Rare Disease | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 28
|
|
$ 54
|
|
| Actual %, year-on-year |
13.00%
|
|
16.00%
|
|
| Other Rare Disease | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 6
|
|
$ 20
|
|
| Actual %, year-on-year |
7.00%
|
|
4.00%
|
|
| CER %, year-on-year |
4.00%
|
|
16.00%
|
|
| Other Rare Disease | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 18
|
|
$ 34
|
|
| Actual %, year-on-year |
20.00%
|
|
12.00%
|
|
| CER %, year-on-year |
16.00%
|
|
12.00%
|
|
| Other Rare Disease | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 3
|
|
$ 5
|
|
| Actual %, year-on-year |
37.00%
|
|
9.00%
|
|
| CER %, year-on-year |
32.00%
|
|
10.00%
|
|
| Total Other medicines |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 241
|
|
$ 508
|
|
| Actual %, year-on-year |
(10.00%)
|
|
(9.00%)
|
|
| CER %, year-on-year |
(9.00%)
|
|
(7.00%)
|
|
| Total Other medicines | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 21
|
|
$ 40
|
|
| Actual %, year-on-year |
(26.00%)
|
|
(23.00%)
|
|
| Total Other medicines | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 186
|
|
$ 392
|
|
| Actual %, year-on-year |
4.00%
|
|
2.00%
|
|
| CER %, year-on-year |
5.00%
|
|
4.00%
|
|
| Total Other medicines | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 16
|
|
$ 35
|
|
| Actual %, year-on-year |
(32.00%)
|
|
(34.00%)
|
|
| CER %, year-on-year |
(38.00%)
|
|
(34.00%)
|
|
| Total Other medicines | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 18
|
|
$ 41
|
|
| Actual %, year-on-year |
(50.00%)
|
|
(41.00%)
|
|
| CER %, year-on-year |
(50.00%)
|
|
(40.00%)
|
|
| Nexium |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 198
|
|
$ 426
|
|
| Actual %, year-on-year |
(10.00%)
|
|
(7.00%)
|
|
| CER %, year-on-year |
(9.00%)
|
|
(5.00%)
|
|
| Nexium | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 18
|
|
$ 37
|
|
| Actual %, year-on-year |
(30.00%)
|
|
(21.00%)
|
|
| Nexium | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 157
|
|
$ 333
|
|
| Actual %, year-on-year |
7.00%
|
|
5.00%
|
|
| CER %, year-on-year |
9.00%
|
|
8.00%
|
|
| Nexium | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 6
|
|
$ 17
|
|
| Actual %, year-on-year |
(49.00%)
|
|
(35.00%)
|
|
| CER %, year-on-year |
(55.00%)
|
|
(35.00%)
|
|
| Nexium | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 17
|
|
$ 39
|
|
| Actual %, year-on-year |
(52.00%)
|
|
(43.00%)
|
|
| CER %, year-on-year |
(51.00%)
|
|
(41.00%)
|
|
| Other, Others |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 43
|
|
$ 82
|
|
| Actual %, year-on-year |
(10.00%)
|
|
(19.00%)
|
|
| CER %, year-on-year |
(11.00%)
|
|
(18.00%)
|
|
| Other, Others | US |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 3
|
|
$ 3
|
|
| Actual %, year-on-year |
12.00%
|
|
(46.00%)
|
|
| Other, Others | Emerging Markets |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 29
|
|
$ 59
|
|
| Actual %, year-on-year |
(12.00%)
|
|
(12.00%)
|
|
| CER %, year-on-year |
(11.00%)
|
|
(11.00%)
|
|
| Other, Others | Europe |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 10
|
|
$ 18
|
|
| Actual %, year-on-year |
(12.00%)
|
|
(32.00%)
|
|
| CER %, year-on-year |
(18.00%)
|
|
(33.00%)
|
|
| Other, Others | Established ROW |
|
|
|
|
| Product sales |
|
|
|
|
| Product Sales |
$ 1
|
|
$ 2
|
|
| Actual %, year-on-year |
4.00%
|
|
8.00%
|
|
| CER %, year-on-year |
(3.00%)
|
|
7.00%
|
|